Every peptide, mapped to the body.

153 peptides, from approved drugs to compounds still in trials, sorted by where they act.

FDA-approved
In clinical trials
Wellness and performance
Cosmetic and topical

Loading the body

In clinical trials

Digestive & weight

Petrelintide

Also called ZP8396

EvidenceModerate research

ClassLong-acting amylin analog

Petrelintide is an investigational long-acting amylin analog studied for weight management. Learn how it works and what the Phase 2 research has shown so far.

Reviewed by: William Maish, MD MBA MPH, Clinical Product Lead
Published: October 5, 2026
Last updated: October 5, 2026

Key takeaway

Petrelintide is an investigational long-acting amylin analog, developed by Zealand Pharma (with Roche) as a once-weekly injection for weight management. In a Phase 2 trial it produced clinically meaningful weight loss over about 42 weeks with gastrointestinal tolerability similar to placebo. As of 2026 it is not approved, with Phase 3 testing planned to begin.

At a glance

FDA status	Investigational peptide, not approved by the FDA or any regulator
What it is	Long-acting amylin analog given as a once-weekly injection
Research	Human evidence is a single positive Phase 2 trial in obesity
Development	Phase 3 registration trials planned but not yet completed
Evidence strength	Moderate research

What is petrelintide?

Petrelintide is an experimental drug that mimics amylin, the pancreatic hormone that signals fullness. It was engineered by Zealand Pharma under the development code ZP8396 for stability and a long half-life suitable for once-weekly injection. It is being developed in collaboration with Roche, including a planned combination study with a separate incretin drug. It is investigational and not approved for any use.

How does it work?

Petrelintide activates amylin receptors¹, reproducing the satiety signaling of the natural hormone amylin. This is associated with three effects that together lower food intake:

Reduced appetite
Slower gastric emptying
Suppression of glucagon

Because amylin signaling is a different pathway from the GLP-1 and GIP incretin systems, petrelintide is also being explored in combination with incretin drugs. This describes the proposed mechanism, separate from whether it improves outcomes.

Is it FDA-approved?

No. Petrelintide is investigational and not approved by the FDA or any other regulator. According to the developers, Phase 3 registration trials are planned to begin, with additional Phase 2 data in people with type 2 diabetes expected.

What does the research show?

The current evidence is a single Phase 2 trial. According to PubMed, the ZUPREME-1¹ trial in people with obesity without diabetes reported mean weight loss at two timepoints:

Timepoint	Mean weight loss
28 weeks	Roughly 9 to 10%
42 weeks	Continuing to around 11%

Mild nausea was the main side effect, and overall gastrointestinal tolerability was similar to placebo. This is one positive, placebo-controlled Phase 2 study; Phase 3 trials have not yet been completed, so longer-term efficacy and safety remain to be established.

More for digestive & weight

Sources: the ZUPREME-1 Phase 2 trial (Garvey et al., The Lancet Diabetes & Endocrinology, 2026, DOI: 10.1016/S2213-8587(26)00213-5¹), indexed on PubMed; and Zealand Pharma development updates. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.